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Wr have described previously the clinical features of a unique 
group of anti-Ro(SS-A) antibody positive Sjogren's patients 
who have cutaneous feam res of lupus erythematosus, most 
commonly subacute cutaneous lupus erythematosus. defined 
a5 th e Sjogren's/lupus erythematosus overlap syndrome. 
Three of these patients are also mothers of infants with th e 
neonatal lupus erythematosus syndrome, characterized by 
cutaneous lesions resembling subacute cutaneous lupus ery-
thematoslls or congen ital heart block. Patients with Sjo-
grt"n's/lupus erythemacosus overlap syndrome, subacute cu-
taneous lupus erythematosus. and mothers of infants with the 
neonatal lupus syndrome characteristicall y have autoantibo-
dies to Ro(SS-A). and in many cases, La(SS-B) antigens. The 
presenr study was designed to test the hypothesis that ami-
Ro(SS-A)/La(SS-B) positive Sjogren's/Iupus overlap pa-
Sjogren \ syndrome and systemic lupus erythematosus arc two autoimmune connective tissue disorde rs with distinc-ti ve, but often overlapping clinical features. Primary Sjo-gren's syndrome is a common autoimmune c:xocrinopathy with glandular 11 .2] and. in some instances. exrra,g landu-
lar or systemic III manifestations. Recendy, vascuJitis and central 
nervous system disease have been described 13,4J. SYStemic lupus 
erythematosus. distinctl y less common than Sjogren's syndrome. 
but be tter recognized. is characccri7.cd by polyserosi tis. glomerulo-
nephri tis. centraJ nervous system discase. and distinct ive cutaneous 
manifestations including photosensitivity. maJar rash, :md discoid 
skin lesions [51. 
Over the past decade. two new syndromes have been recognize.d 
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AbbreViations: 
HLA: huma.n IcucOC}'[e antigen 
55-A: Sjogren's s)'ndromc :anti gen A 
5S-I$: Sjogren's syndrome antigen B 
S5: Sjogren's Synd rome 
LE: lupus erythematosus 
NLE: neonat:aJ lupus erythematosus 
tients and mothers of infants with neonatal lupus erythema-
tOSUS syndrome are immunogeneticaIly homogenous and 
closely related. We report a strong association with HLA-B8, 
DR3, DQw2, and DRw52 phenotypes and the HLA-B8, 
DR3, DQw2, DRw52 extended haplotype in both patient 
cohorts. Furthermore, we describe disease associations with 
HLA-DR3/ DRw6 heterozygotes in both patient groups. 
These data demonstrate that anri- Ro(SS-A)/ La(SS-B) posi-
tive Sjogren's/Iupus overlap patients and neonatal lupus syn-
drome mothers are immunogenetically closely related to 
each other and appear to be more closely related to both 
primary Sjogren's syndrome and subacute lupus erythemato-
sus. than to classical systelnic lupus erythematosus. J Invest 
Dermalol 93:75 1- 756, 1989 
which havf" been considered to be rdated closely to classical sys-
temic lupus erythematosus: subacute CUUneous lupus erythemato-
sus and the neonatal lupus syndrome. Subacute cutaneous lupus is 
predominantly a cutaneous disorde r characte.rized by a photosensi-
tive dC'rmatitis with annular. polycyclic, or psoriasiform lupus le-
sions [6.7J. Systemic compl ica tions. characteristically present fre-
qucntly in systemic lupus erythcmatosus, are uncommon in 
subacutc cutaneous lupus erythematosus [6]. An association of sub-
acute r UC3n("Ous lupus erythematosus with Sjogren's syndrome has 
not been observed previously [8}. 
The neonatal lupus syndrome is characterized by transient lupus 
lesions which are similar, if not identical. clinically and histopatho-
logically, to the annular cutaneous lesions seen in subacute lupus 
erythC"matosus [9,10]' Other infantS with rhe neonatal lupus syn-
drome develop partial or complete hean block in utero or in the 
neonatal period. In f.act , the neonatal lupus syndrome is rhe most 
common cause of isolatC'd congenital heart block Ill]. Approxi-
m ately 60% of mothers of infants with the neonatal syndrome are 
asymptomatic at the time of the birth of the affected child . Subse-
quently, many of the asymptomatic mochers develop Sjogren's syn-
drome or lupus erythematosus or both, although this may nO{ occur 
until man}' years after the birth of the infant with neonatal lupus 
syndrome 11 2. 13]. 
Sjogren's syndrome and these lupus subgroups appear to be linked 
sero logically. Patients with primary Sjogren's syndrome and sub-
acute cutaneous lupus erythematosus. as well as neonatal lupus ery-
thematosus mothers. produce autoantibodies to the small molecular 
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weigh , ribonuclear proteins La(SS-B) and/ or Ro(SS-A). Pr<vious 
reports have demonstrated that approximateJy 45% of primary Sjo-
gren's syndrome patienrs I14]. 70% of patients with subacute cuta-
neous lupus erythemarosusl7J. and 95% ofthc neonataJ lupus ery-
thematosus mothers have ami-Ro(SS-A) antibodies [9.10.t5]. The 
La(SS-B) antibody is found in approximately 15% of primary Sjo-
gre-n's syndrome 114). 36% of subacute cutaneous lupus erythema-
tosus patients [7J. and 60% of neonatal hlpus erythematosus infants 
ItS). Other investigators. however. have nor observed a h.igh fre-
quency of anti-Ro(SS-A)/ La(SS-B) antibodies in subacute cutane-
ous lupus erythematosus syndrome in a nonreferral setting (t 6.17J. 
Recently we have described the dinical features of a unique group 
of anti-Ro(SS-A)/ La(SS-B) posi,ive Sjogren 's syndrome patienrs 
who have prominent Clltaneous features of lupus erythematosus 
\18J; particularly, the annular polycyclic cutaneous lesions of sub-
acute cutaneous lupus erythematosus. As a group. these patiems 
have a high frequency of sys temic complications, particularly vascu-
litis (peripheral or systemic) and nervous system disease. However, 
they usually do not develop classical systemic complications of sys-
temic lupus erythematosus. i.e., polyserositis, acute glomerulone-
phritis, lupus psychosis, or seizures. O ur Sjogren'sj lupus erythema-
msus overlap patients all have antibodies (0 Ro(SS-A) and 60% have 
anti-I....a{SS-B) antibodies, bur rarely have other antibodies classical1y 
associated with sys temic lupus erythematosus (i.e. antibodies to na-
tive DNA, nRNP, or Sm), Preliminary studies [20) have indicated 
that 'hese ami-Ro(SS-A)/La(SS-B) positive Sjogren 's/ Iupus overlap 
patients also afe relatively homogeneous immunogenetically shar-
ing an increased frequency of HLA-B8, DR3, and DRw52 pheno-
types. specificities most often associated with primary Sjogren's 
syndrome 121J, rather than systemic lupus erythematosus (HLA-
DR2) [22-261. 
The prescnr study was designed to examine the immunogenetics 
of anti-Ro(SS-A) positive Sjogren's syndrome/ lupus erythematosus 
overlap patients and neonatal lupus syndrome mothers (ei ther cuta-
neous N LE or congenital heart block). These studies expand Our 
published preliminary observations on HLA phenorypes in 8 Sjo-
gren's syndrome/lupus erythem:a osus overlap patients and 19 neo-
naul lupus mothers. The hypothesis is tested thar these clinically 
and serologically telated anti-Ro(SS-A)/ La(SS-B) positive patient 
subgroups are immunogenetical ly relatively homogeneous and 
closely related [Q each other . In th is study it was determined that the 
two patient cohorts are more closely immunogenetically linked to 
primary Sjogren 's syndrome and subacute cutaneous lupus eryt hem-
atosus than to systemic lupus erythematosus. 
METHODS 
Patient Groups The patient groups consisted of 17 female pa-
tients (14 caucasoids, 3 blacks) with definite Sjogren's syndrome 
who aJso had one or more cutaneous manifestations of lupus ery-
thematosus (subacute cutaneous lupus erythematosus, photosensi-
tivity, malar rash , or discoid skin lesions) and 21 mothers (17 cauca-
soids. 3 blacks, 1 hispanic) of infants with neonatal lupus syndrome 
(14 with cutaneous disease and 7 with congenital heart block). 
Three Sjogren's/ Iupus erythematosus overlap syndrome adults 
wcr(' also the mothers of children with the n.eonatal lupus syn-
drome. The patients were referred to I:uge tertiary refern! centerS in 
the Department of Dermatology and (he Divisions of Rheunutol-
ogy and Clinical Immunology at Johns Hopkins (n = 26) and the 
Divisions ofRheunulology at the Univers ity ofOklahonu (n = 2) 
and the University of Texas at San Antonio (n = 1). Six NLE 
mothers were evaluated at the Universicy of Colon do. The control 
group consisted of local caucasoids (see HLA typing) . 
Patients ca tegorized as having Sjogren's syndrome were sympto-
matic for the sicca complex and had an abnormal opthalmologic 
examination (Schirmer's test or Rose Bengal dye test) or positive 
minor salivary gland biopsy. or both l2,27]. Criteria for diagnosis of 
Sjogren's syndrome and the documentation of nervous system dis-
ease and vasculitis have been published in detail elsewhere 13,41· 
Clinical dara on 10 of 17 an'i-Ro(SS-A) positive Sjogren's/Iupus 
ery thematosus overlap patients has been published previously [18]. 
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The diagnosis of subacute cutaneous lupus erythematosus was 
made using the criteria set forth by Sontheimer et a1 {6]. a.nd th~ 
diagnosis of indolent (discoid) cutaneous lupus lesions. by detecting 
the characteristic morphologic features. The diagnosis of cutaneous 
lupus lesions was confirmed by sk.in biopsy. Four pa tients met four 
criteria for sys temic lupus erythematosus [5}. 
Serologic Studies All Sjogren's/lupus erythematosus overlap 
syndrom.e patients and neonaul lupus syndrome mothers were ex-
amined for the following autoantibodies: nuclear, natjve deoxyri-
bonucleic acid (nDNA), Sm, U,RNP(nRNP), and Ro(SS-A) using 
immunofluorescenc~ and gel double diffusion techniques as de-
scribed previously l14}. All Sjogren's/lupus erythematosus overlap 
syndrome patients and 13 of21 neonatal lupus mothers were exam-
ined for anti-La(SS-B) antibodies. These serologic studies have been 
reported in part previously !15.1 8.281. 
HLA Typing HLA-B aJloantigens were determined by a standard 
complement-dependent microcytotoxiciry assay. Typing for HLA-
DR and DQ specificities was performed using a rwo-color fluores-
cence method [25,29). Each patiem was tested for 34 H LA-B 31-
loamigensand forDR I-DRwI O, DQw l , DQw2, DQw3, DRw52, 
and DRw53 using ryping sera chat were obtained from local (Dr. 
Wilma Bias) and other private sources, and were standardized 
against the typ ing se ra of the 8th and 9th Internacional Histocom-
patibiliry Testing W orkshops. HLA-ryping on eight of the 17 Sjo-
gren's/lupus overlap syndrome patients and 19 of the 2 1 neonatal 
lupus mothers have been published pr~viousl y [15.20,281. Controls 
consisted of 3761 (HLA-B) and 1094 (H LA-DR, DQ, Drw52, 
DRw53) local caucasoids. 
Extended haplocypes in this study were defined as the occurrence 
in an individual ofHLA phenotypes known to be in linkage disequi# 
librium and associated with the observed superrypic specificity. Al-
though family studies were not performed, due to linkage disequi-
librium, jt is more than likely that HLA-B8, DR3. DQw2. an.d 
DR w52 are syngeneic or coupled. 
Statistjcal Analysis All patients were categoriz.ed clinically inde-
pendent of knowledge ofHLA-ryping and conversely HLA ryping 
was performed independent of clinical diagnosis. Fisher 's exact test 
(two-tailed) was used for statistic:ll comparisons between groups. 
T he p values were corrected for the number of individual HLA 
antigens assayed. Relative risks were determined by the odds ratio 
method. 
RESULTS 
Clio,ical Features The clinical features of the Sjogren's syn-
drome/lupus erythematosus overlap patients are presented in Table 
1. The development of one disorder usu;tlly antedated the devdop-
Table L Clinical Fea tures ofSSjLE Patients (n = 17)" 
Clinical Manifestation No. Patients. (Perctnt) 
Sicc~ syndrome 17 (100) 
C UtdneOUS lupus lesions 16 (94) 
SCl£ (n - 10) 
I)hotostnsitiv,ty (n = \0) 
DlE (n - 2) 
Vasculi tis' 6 (35) 
C utaneous (n =: 6) 
Systemic (n = 5) 
Systemie disease 14 (83) 
CNS/PNS' 7 (4 1) 
Renal disease 5 (30) 
Ren:d tubular acidosis (n - 2) 
Glomerulonephritis (n - 2) 
Vuculitis (n ~ I) 
NLE infa,nts 3 (17) 
• Thr clmlcal fc:uuf~ (If 10 of th~K p2titnu have been publi5h~d prtyi(lusly 118). 
~ .All had leukocytOclutic v.uculitis. 
• Cc:ntnl Nervous SY$[cm/~riphcnl nervous system. 
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Table ll. HLA Phenoty~s of Sjogn:n's Syndrome Lupus Eryw enutosus Overlap Patients (n = 17) 
95% Confidence 
H LA-Typ< Patients Interval 
N % 
B7' 2 12 4 - 46 
D8' 11 69 41- 89 
DR2 2 12 1-36 
DR3 13 76 50-93 
ORw6 9 53 28-77 
DR3/DRw6 6 35 14 -62 
DR3 or DRw6 16 9' 71-100 
DQwl 10 59 33-82 
DQw2 13 76 50-93 
DQwl /2 7 41 18 -67 
DRw52 17 100 80-100 
• Controls: N - 3761 (or lilA-B: N - 1094 for HLA-D R, DQw, :lIid DRw52. 
• IlR: Hduive rISk (lr odd~ ratio. 
• p v:!.lue for rwo-t:.I.ilcd Flsh~r's cx:!.(.1 prob;lbilit)' ICSt. 
l N : 16 fOT HLA-B ryping; 15 for HLA·C Iyping. 
lnem of the other by several years, ranging up to 30 to 40 years. 
Eight patients had Sjogren's syndrome initially and 6 had lupus 
erythematosus initially. Three patients developed manifestations of 
Sjogren 's syndrome and lupus erythematosus simul taneously. Six-
teen (94%) patients had cutaneous lesions of lupus erythematosus. 
Subacute lupus eryrhcmamsus and photosensitiviry were the: fWO 
most common cutaneous manifestations, each present in 10 pa· 
ticnrs. Cutaneous vasculitis, of the neutrophi lic type (i.e., leukocy-
coclastic), previously associated with anti-Ro(SS-A) antibodies , was 
present in 6 patients [30]. 
Systemic complications were common, occurring in 14 (83%) 
patients and included central or peripheral nervous system disease 
(0 = 7), systemic vasculi tis (n = 6), and renal disease (n = 5). Three 
of thesf' Sjogren'sJlupus erythematosus overlap patients had given 
birth to infants with the neonlltallupus syndrome: cutaneous (n = 
1) and congenital hean block (n = 2). 
Serologic Features All Sjogren's syndrome/ lupus erythematosus 
patients had antibodies to Ro(SS-A), while 8 (470/0) also had anti-
bodies to La(SS-B). All mothe.rs of infants with neonatal lupus ery-
thematosus syndrome had antibodies to Ro(SS-A), while 8 of 13 
(61%) neonatal lupus mothers tested had antibodies to La(SS-B). 
One patient with Sjogren's syndrome/ lupus erythematosus overlap 
syndrome had antibodies to nONA. No Sjogren'sjlupus eryrheDla-
tasus overlap syndrome. patient or neon:aal lupus mother had anti-
bodies to nHNP or Sm. 
ControlS- RR' p Values< 
N % 
901 24 0.42 N5 
780 12 8.4 1.7 X 10-3 
286 26 0.4 N5 
258 24 10.5 7.7 X 10-' 
255 23 3.7 N5 
34 3 17.0 1.4 X 10-
515 47 18.0 6.2 X 10-4 
692 63 0.8 N5 
458 42 4.5 1.3 X 10-2 
184 17 3.5 5.1 X 10-2 
690 63 >20 8.6 X 10--
HLA Pbenorypes - Sjogren's/ Lupus Erytbematosw Over~ 
lap Syndrome The results of HLA typing are presented in Table 
II for the Sjogren's syndrome/ lupus erythematosus group. T here 
was a significant increase in H LA·,88, DR3, DQw2, and DRw52 
alloantigens in the patient group compared to controls with relative 
risks ranging from 4.5 to 20.0. The superrypic specificity HLA~ 
DRw52 was present in all patients (p = 8.6 X 10-.4), 
HLA·DR3 occurred in 13 (76%) patients with Sjogren's/lupus 
erychem,uosus overlap syndrome. Sixteen (94%) of the SS/ LE pa~ 
tienrs were either HLA-DRw3 or DR6 and there was a high fre-
quency (35%) of H LA-DR3/ DRw6 he terozygotes (relative risk = 
17). H LA-DQw l / DQw2 heterozygotes we re increa.sed t O:l. iesser 
extenr [i.e., 7 of 17 (41%)] with a relative risk of3.5. H LA-B7 was 
presC""m in twO patients and HLA·DR2 was seen in only fWO pa-
tients. Thus, both of these alloantigens were negatively associated 
with this anti-Ro(SS-A) positive Sjogren's/Iupus overlap group. 
There was also a negative association wi th H LA-DQw l , which is in 
linkage disequilibrium with H LA-DR2. There was only one HLA~ 
DR2/ DR3 heterozygote (p = 0,7). No significant differences were 
observed when the three black Sjogren 's/Iupus erythematosus over-
lap patients were removed from this anaJysis. 
HLA-Phenotypes- Mothers of Neonatal Lupus Erythema~ 
tosus Infants Table ITl presents the HLA data on the mothers of 
infants with the neonatal lupus syndrome. T he following HLA 
alloanrigens were significantly increased in the neonaral lupus syn~ 
Table ill. HLA Phenotypes of Mothers of NLE Inf.nts (Cutaneous and CH B) (N = 21) 
95% Confide.no: 
HLA-typ< Patients interval 
N % 
B7 4 19 5-42 
118 17 81 53-92 
DIU 4 19 5-42 
DR3 17 81 58-95 
D Rw6 7 33 15-57 
DR3/ DRw6 5 24 8-47 
DR3 or DRw6 19 90 70-99 
DQw l J 11 55 32-77 
DQw2" 19 95 68-99 
DQw l/2' 9 45 23-68 
DRw52 20 95 76-100 
• Controls: N - 3161 (Of HLA·B~ N - 1094 for HLA-DR, DQw. :md 01\w52. 
• RH: rebuvc risk or odds ratio. 
'p yalue for Iwo--t:.I.iled Fisher 's CUCt prob;lbility res!. 
IN; 20 for DQw t.yping. 
ControlS- RR' p Values< 
N % 
90 1 24 0.7 NS 
780 21 12.2 3.3 X 10-& 
286 26 0.7 N5 
258 24 13.8 6.9 X 10- 7 
255 23 1.6 N5 
34 3 9.7 5.4 X 10- 3 
515 47 10.7 4.6 X 10--
692 63 0.7 NS 
'58 42 26.4 2.9 X \0- 1 
184 17 4.0 1.0 X 10-2 
690 63 11.7 1.8 X 10-3 
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drome mothers. in Contrast to the normal controls: HLA-B8. DR3, 
DQw2. and DRw52 with rdacivt' risks ranging from 11.7 to 26.4. 
Twt'nry (95%) of the 21 neonatal lupus syndrome mothers had the 
,upcrtypic 'pecificity HLA-DRw52, while 17 (81%) were HLA-
DR3. The frequency ofHlA-DRw6 (53%) approached, bucdid nor 
teach, statistical significance (i.e., p = 8.3X 10-~). Nineteen (90%) 
of the patients were either HLA-DR3 or DRw6 and there was an 
[creased proportion (24%) of thost who were HLA OR.3/ DRw6 
heterozygore< (p = 5.4 X 10-', relarive risk of9.7). HLA-DQwl j 
2 heterozygotes were increased to a lesser extent compared to con-
rrol, (p = 0.01) wirh a relarive risk of 4.0. HLA-B7 and HlA-DR2 
were presem in onJy four patients. (t 9%) with negative relative risks 
(0.8 and 0.7, respectively). Likewise, HLA-DQw1 was negarively 
associated. There were omy two HLA~DR2/DR3 het~.rozygotes 
(p = 0.22) . There were- no significant differences in the frequency 
of other HLA-DR phenotypes between mothets of infants with the 
cutaneous and the cudiac fonn of the neo n2ul lupus syndrome. 
When rhe three SS/ LE mothers who also had infants with neonatal 
lupus erythematosus syndrome w~rc removed, tbe frequency. sig-
nificance, and relative risks o( the HLA associations did not change 
appreciably. 
E~t.nded H.plocypes-HLA-B8, DR3, DQw2, DRw52 
T able 4 summarizes the frequency of individuals in each patient 
group with ,he extended haplotype HLA-B8, DR3, DQw2. and 
DR w52. T en o( 16 (63%) Sjogren's syndrome/lupus erythematosus 
parie-lUs had this haplotype with a relative risk of 9.5 (p = 
2.4 X 10- '). Likewise. IS of 20 (71 %) mothers of infants wirh rhe 
neonatal lupus syndrome- possessed this haplotype with a relative 
risk of 11.3 (p = 1.8 X 10-'). 
DISCUSSION 
We describe the immunogenetic similarities of .and relationship 
berween two subgroups of clinically and serologl(:aJly related pa-
rients, i.e., anri-Ro(SS-A)j la(SS-B) po,itive parients wirh Sjo-
gren's/ Iupus erythemarosus overlap syndrome and anri-Ro(SS-A)/ 
La(SS-B) positive neonatal lupus syndrome mothers. The data 
indicare thar borh of rhese c1o,ely relared anri-Ro(SS-A}/ la(SS-B) 
positive patient subgroups are immunogenetically more homoge-
nous {han previously described patient groups with either primary 
Sjogren's syndrome or systemic lupus erythematosus {21 - ~3}. Fur-
thermore. both o( these patient cohorts are more closely hoked to 
primary Sjogren's syndrome and sub2CUte cutaneous lupus erythem-
atosus, than to classical systemic lupus erythematosus. 
The complex and dyn<lmic inter-relationship between these pa-
tient subgroups is diagrammed concepru~lIy in Fig 1. A com.mo~ 
clinical fearure shared by both of these patIent subgroups are promI-
nent cutaneous manifestations of lupus. i.e .• photosensi tivity and 
subacutt cutaneous lupus lesions. The diagram also illustrates that 
patients with identical HLA phenorypes and autoantibody expres-
sion can change their clinical phenotype unpr~dic{ably over long 
periods of time (spanning more than 40 re~rs). Ftgure 1 al so empha-
sizes that anti-Ro(SS-A)/ La{SS-B) posmve mothers of neonatal 
lupus in(:!nts, many of whom are asymptomatic at th~ time.of (he 
birth of their affected infants, eventually devc\op Sjogren s syn-
Table IV. Frequency of rhe Extended Haplotype, in SS/LE and 
Mothers of NLE lnfants 
P:lticni Group 
(N) 
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Figure 1. Interrebtionahip of Anti-Ro (S5-A}/ L:t(SS-ll) poSitive female 
HLA-OR3 and/ or DRw6 positive suhacute cur.ancOU$ lupus. neon.at;tllupus 
mothers .and Sjogrcru/Lupus crythem.arosus overlap p.niC'IHs . 
dromt':. lupus erythem3cosus (with prominent subacute cutaneous 
lupus lesions), or both of these di.sorders. These dynamic and evoiv-
ing inter-rel2tionships underscore the potentbl difficulties in classi-
fying patients on clinic21 criteria alone, particularly at one point 1n 
time. Furthermore, the data suggeSt that autoantibody profiles and 
HLA-ryping may be useful clinically in defining patient cohorts. 
Sjogren's syndrome ;md systemic lupus eryt~ematosu~ are two 
autoimmune connective tissue disorders in wi\tch genct:\c factors 
appear {Q be involved in disease susceptibility. Multiple genes have 
been implicated, including major histOcompatibility , complement, 
and T cell rec~ptor genes. as well as an autosomal dominant autoim-
Inunr gene PI}. HLA Class II D region associations have been 
reported in both Sjogren's syndrome and systemic lupus erythema-
tosus, but have been rdatively weak with low relative risks. In 
caucasoid systemic lupus eryrhemacosu5 patients, th.c most co~sis~­
ent corrc-lations arc with HLA-DR2 and DQw l (llllkcd specifiCi-
ties) and HLA-DR3, each of which confers .. relative risk of approx-
imately 2 to 3 {22,24,32]. Sjogren's syndrome is associated with 
HLA-B8 :md even morc strongly with HLA-DR3 (relar.ive risk 4) 
and the superrypic specificity HLA-DRw52 (relative risk 22) 
121,33}. Anti~Ro(SS-A) positive subacute cutaneous lupus: erythem-
atosus, particularly the annular polycyclic lesions. has been reported 
to be strongly associated wi th HLA-DR3 (relative risk 12) (7.8). 
although other investigators sampling a nonreferral patieot popula-
tion have not confirmed these associations \16,17}. Anti-Ro{SS-A}/ 
La(SS-B) positive mothers of infants with the neonatal lupus syn-
drome are predominantly HLA-DR3 (relative risk 8.0) , while 
anti-Ro(SS-A) posi tive HLA-DR2 mothers appear to have a low 
risk of having an inf;mt with the neonat311upus syndrome it 5]. 
In the presem study we have established a strong immunogenetic 
relationship of the: Sjogren 's/Iupus erythematm.us overl<tp syn-
drome and neollatal lupus syndrome with HLA class II alJoaDtigens 
associated mOSt commonly with primary Sjogren's syndrome, 
rather than classical systemic lupus erythematosus. In the Ro(SS-
A)/ La(SS-B) positive Sjogren's lupus ovcr1a~ ~atients a~d .neona.tal 
lupus syndrome mothers, we observe a stnkmg asSOCiation With 
HLA-B8, DR3. DQw2. and DRw52 alloantigens. and the extended 
haplotype HLA-B8. DR3. DQw2. DRw52. There is a sign ificanr 
negative association with HLA-B7, DR2 and DQwl. phen~types 
associated with classical lupus erythematosus and observed m ap-
proximately 50% of ,II anti-Ro(SS-A) parients [22 -261· 
In addition, these studies expand our preliminary publ ished re-
ports on a possible new association of the Ro(SS-A) positive Sjo-
gren's/Iupus overlap patients wi th the HLA-DRw6 phenorype r20} 
(essentially all patients were either HLA-DR3 or DRw6) and of 
HLA-DR3/ DRw6 heterozygosity with both Sjogren's/ Iupus over-
lap patients [20} and neonatal lupus mothers. An increased (re-
quency of HLA~DQw2/ 1 (each in linkage disequmbrium wich 
HLA-DR3 and DRw6, respectively) heterozygotes was also ob-
served in both Sjogren's/Iupus o.verlap patients and in the neonataJ 
lupus syndrome mothers (relative fisk = 3.5; 4.0), but was l ~ss 
striking than the &equency of HLA-DR3/ 6 hetcrozygotes {relatJve 
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risk = (17; 9.7)\. HLA-DQwl / 2 heterozygosity in Sjogten's syn-
drome and systemic lupus erythematosus has been linked to high 
antibody response to La.(SS~B) and/or Ro(SS-A) antigens with a 
rela.tive risk of approximately 3.0 \34,351. 
These irrununogenetic observations were not entirely predictable 
from previous data, given the fact that both HLA-DR2 and, to a 
lesser c.xtem, HLA-DR3 are increased i.n systemic lupus erythema-
tosus [27 ,28] and both HLA-DR2 and DR3 are associated with 
anti~Ro(SS-A) antibodies 125,32]. Three main possible Outcomes 
with respect to HLA-DR ph-enorypes were possihle in this study. 
Firsr , the Sjogren's lupus overlap padent cohort may have had the 
HLA-DR2 phe.notypc most commoruy associated with systemic 
lupus erythematosus [22 - 26] and present in a signific:tnt number of 
ami.Ro(SS-A) positive ind ividuals with lupus l25J. Second. the pa-
tient groups may have shared immunogenetic HLA-DR pheno-
types of both primary Sjogren's syndrome (HLA-DR3) and sys-
temic lupus erythematosus (HLA-DR2) resulting in a high 
proporrion of HLA-DR2/ 3 heterozygotes , a phenotyre associated 
with antibody production to Ro(SS-A) in lupus !35 . Thitd, the 
patient groups may luve been more closely linked immunogeneti-
cally with primary Sjogren's syndrome than with classical lupus 
erythematosus. The latter outcome was documented j"n the present 
study for both patient groups. 
These and previous data suggest that cerrain cutaneous manifesta-
tions (i.e .. photosensitivity and subacute cutaneous lupus erythema-
tosus) considered to be parr of the clinical spectrum of lupus ery-
themacosus, actually are occurring in the HLA Class II D r~gion 
immunogenetic background of Sjogren's syndrome, rather than 
lupus erythematosus. Although previous genetic swdies of subacute 
cutaneous lupus ery thematosus by Sontheimf'r er a1J7] identified a 
high frequency of HLA-A 1, BB. DR3, only cwo of 17 patients had 
objective evidence of the sicca complex and Ilone had dennite Sjo-
gren's syndrome. Thus, these subacute cutaneous lupus erythemaro-
sus patients we.re not categorized as having an overlap syndrome. 
These patients may be distinct from the overlap patients described 
herein or subsequently may have developed Sjogren's syndrome. 
This Janer issue is currendy being reinvestigated (Sontheimer ec al. 
personal communicarion) . The data also suggest, as have previous 
studies 135j, that HLA-DR2 and HLA-DR3 associated sysc('mjc 
lupus erythematosus may be different cl inical subsets of disease , the 
larrer more closely linked to Sjogren's syndrome. 
The previous inability to denne more specific ;).ssociations be-
rw{'{'n HLA-D regions genes and disease susceptibility in lupus ery-
themarosus and. to a lesser extent in Sjogren's syndrome, m,y be 
due , in part , to the clinical heterogeneiry of previously studied pop-
ubtions. Second. patient subgroups felt to be clinically distinct actu-
ally may share nosologic features which unify them. This appears to 
be the case with anti-Ro(SS-A) positive Sjogren's syndrome patients 
who develop promincnr cutaneous features oflupus erythematosus 
and may give birth to neonatal lupus syndrome infants. Third. the 
detection of se rologic specificities for certain HLA allotypes, has 
improved oyer the last several years. permitting more complete and 
accurate typing. Finally. other alleles, new class 11 antigens formed 
by gene cODve.rsion, or disease specific epitopes 136], may be more 
closely linked to disease expression than currently identi.fied 
HLA-D Tegion associ:ltiom. 
The identification of a clinically. serologically. and immunogen-
etically relatively homogeneous group of patients is important for 
seveTal Teasons. First , this study strongly suggests that the Sjo-
gren's/I upus erythematosus overlap syndrome. neonatal lupus ery-
thematosus syndrome, and subacute cu taneous lupus erythematosus 
may be more closely linked immunogenetically to primary Sjo-
gren's syndrome (han to classical systemic lupus erythematosus. 
Second, these observations provide a conceptual framework upon 
which to begin to modify our classification and understanding of 
the relationship between these disorders and their pathogenesis. 
Third. the potentia l new association with HLA-DRw6, particularly 
iu anti-Ro(SS-A)/ La(SS-B) positive Sjogren's/ Iupus overlap pa-
tients. who are nOt HLA-DR3. may provide an addirional HLA~DR 
region alloanrigen marker. Furthermore. the increased relative risk 
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associated wirh HLA~DR3/Dw6 hete rozygotes is remiruscenr of 
the association of other heterozygous states with autoimmune dis-
eases [i.e., insulin-dependent diabetes mellitus (HLA-DR3/ DR4)] 
\37 ,38] and pemphigus vulgaris (HLA-DR4/ Dw6) [39,40]. Im-
munogenetic studies at a molecular level are in progress ro further 
analyze HLA-D region associations with Sjogren's/ lupus erythem-
atosus overlap syndrome and neonatal lupus syndrome. 
TJl t autl,on WOIIIJ likr to thallk Drs. Al Lant , John Harl~, Ltl., Ut, Norman 
Tala!, Gail McCa rry, jolm Strahan, Ron BOSI, .",d Dallid VasilyJor loruributingor 
ufi'rring patitllu. Til l' txprrt ""d profess;onal clerical assistance oj Vicky Ro~rs, 
Wt PlIly Baktr, a"d T eri Momgomtry is apprtcitu.ed. 
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